RxDoctor Payments Data

Imran Hasnain, MD

Internal Medicine · Corona, CANPI 1003850553

Payments from drug & device makers

$369in general payments, 2019–2025

Across 9 payments — averaging $40.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$118
  • Novo Nordisk$114
  • Boehringer Ingelheim$66
  • Pfizer$23
  • Lilly USA, LLC$20
  • AstraZeneca$15
  • plus $13 from 1 others

What the payments were for

  • Food & beverage$369100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK1$118
Novo Nordisk1$114
Boehringer Ingelheim3$66
Pfizer1$23
Lilly USA, LLC1$20
AstraZeneca1$15
Abbott1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$369 in reported general payments places this provider in the 60th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$80,790
Medicare patients
127
Services billed
715

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide93$112,091
OzempicSemaglutide81$103,167
JardianceEmpagliflozin104$98,982
EliquisApixaban83$50,175
JanuviaSitagliptin Phosphate85$46,487
LinzessLinaclotide25$19,342
TradjentaLinagliptin14$18,367
XareltoRivaroxaban17$14,744
Pantoprazole Sodium105$13,592
Scopolamine45$6,109
Acetylcysteine31$5,635
Famotidine129$5,635
Enoxaparin Sodium57$5,117
Atorvastatin Calcium410$4,901
Dantrolene Sodium30$4,674

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$66$117,349118 claims
Lilly USA, LLCTrulicity$20$112,09193 claims
Novo NordiskOzempic$114$103,16781 claims
PfizerEliquis$23$50,17583 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Corona

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →